Difference between revisions of "Comparison criteria"

From Testiwiki
Jump to: navigation, search
(commenting tool added)
Line 4: Line 4:
 
== Question ==
 
== Question ==
  
−
Which comparison criteria should be used for pneumococcal conjugatevaccines in the tendering process in the autumn of 2014, in which(?) a vaccine is aquired for the national vaccination programme for children?
+
Which comparison criteria should be used in the  
−
* Possible comparison criteria include prize, benefits(?), safety and technical properties.
+
tendering process for the selection of a pneumococcal conjugate vaccine to be included in  the national vaccination programme for children in Finland?
−
** Prize refers to the bargaining prize of the vaccine.
+
(The tendering process will be initiated during autumn 2014.)
−
** Benefits refers to the decrease in desease burden caused by large scale use of the vaccine. As a result the quality of life connected to health increases and health care costs decrease.
+
* Possible comparison criteria include price, benefits, safety and technical properties.
 +
** Price refers to the bargaining price of the vaccine.
 +
** Benefits refer to the decrease in disease burden caused by large scale use of the vaccine. As a result health care costs decrease and the quality of life attributed to improved health increases.
 
** Safety
 
** Safety
 
** Technical properties
 
** Technical properties
−
* The benefits of the pneumococcal conjugate vaccine can be assessed by the decrease of desease caused by pneumococcus and Haemophilus influenzae -bacteria.
+
* The benefits of the pneumococcal conjugate vaccine are quantified by the decrease of disease caused by pneumococcus and Haemophilus influenzae -bacteria.
−
* The benefit is assessed in the entire Finnish population.
+
* The benefits are assessed in the entire Finnish population.
  
 
== Answer ==
 
== Answer ==
  
−
The original proposal is that the comparison of the vaccines will concentrate on the prize and the assessed benefits. Benefit is assessed according to invasive pneumococcal deseases. Hyötyä arvioidaan invasiivisen pneumokokkitaudin perustella.
+
The tentative proposal is that the comparison is based on price and assessed benefits. Benefits are quantified as the expected decrease in invasive pneumococcal disease incidence due to vaccination.  
−
 
+
The tentative proposal is the basis for the conversation beginning in the summer of 2014.  
−
This original proposal is the basis for the conversation beginning in the summer of 2014.  
 
  
 
== Rationale ==  
 
== Rationale ==  

Revision as of 10:04, 8 July 2014

Progression class
In Opasnet many pages being worked on and are in different classes of progression. Thus the information on those pages should be regarded with consideration. The progression class of this page has been assessed:
This page is a draft
The relevat content and structure of the page is already present, but there still is a lot of missing content.
 This page needs a curator. Learn more about curating Opasnet pages.


Question

Which comparison criteria should be used in the tendering process for the selection of a pneumococcal conjugate vaccine to be included in the national vaccination programme for children in Finland? (The tendering process will be initiated during autumn 2014.)

  • Possible comparison criteria include price, benefits, safety and technical properties.
    • Price refers to the bargaining price of the vaccine.
    • Benefits refer to the decrease in disease burden caused by large scale use of the vaccine. As a result health care costs decrease and the quality of life attributed to improved health increases.
    • Safety
    • Technical properties
  • The benefits of the pneumococcal conjugate vaccine are quantified by the decrease of disease caused by pneumococcus and Haemophilus influenzae -bacteria.
  • The benefits are assessed in the entire Finnish population.

Answer

The tentative proposal is that the comparison is based on price and assessed benefits. Benefits are quantified as the expected decrease in invasive pneumococcal disease incidence due to vaccination. The tentative proposal is the basis for the conversation beginning in the summer of 2014.

Rationale

The procurement law(?) only allows clearly demonstrated differences proportionable to the benefits of products as comparison criteria. Practirally often especially so called technical differences cannot be taken into account. There have been no differences in the safety demonstrated in licenced pneumococcal conjugate vaccines.

See also

Tendering process for pneumococcal conjugate vaccine
Parts of the assessment

Comparison criteria for vaccine   · Epidemiological modelling   · Economic evaluation

Background information

Sensitivity analysis · Replacement   · Pneumococcal vaccine products   · Finnish vaccination schedule   · Selected recent publications

Help for discussion and wiki editing

Pages in Finnish

Pneumokokkirokotteen hankinta  · Rokotteen vertailuperusteet · Epidemiologinen malli · Taloudellinen arviointi · Pneumokokkirokotteen turvallisuus

Work scheduling · Monitoring the effectiveness of the pneumococcal conjugate vaccine · Glossary of vaccine terminology


Comment the content

Current comments that have not yet been included in the main page or talk page.


You can give comments about the content without login simply by writing your comments into the text box below. The page moderator will include your comments in the actual content of the page and then moves the comment to the archive:


Your comment about the page content or discussion:

To what part of the page does you comment refer?:

Comments to be removed (after they have been moved to the page text)

ID of the comment to be removed:

Reason to remove:

Retrieved from "http://www.opasnet.org/testiwiki/index.php?title=Comparison_criteria&oldid=32056"